Drugs / IGSC 20%
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03814798 | Dec 2019 → Sep 2020 | immunodeficiency disease | Grifols Therapeutics LLC | Withdrawn | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT04566692 | Nov 2020 → Jul 2022 | immunodeficiency disease | Grifols Therapeutics LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGSC 20% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04566692 ↗ |
| Modality | Protein / enzyme biologic | “Biological: IGSC 20%” NCT04566692 ↗ |
| Route | Subcutaneous | “using an infusion SC pump” NCT03814798 ↗ |